Amsterdam UMC

• SAFEST Not authorised
  2022-502059-79-00 Phase IV 1 country ATORVASTATIN
• Treating discharge and discomfort of eye prosthesis: a comparison between vitamin A ointment, anti-inflammatory eye drops and standard eye d… Not authorised
  2023-504451-27-00 Phase IV 1 country FLUOROMETHOLONE; SODIUM HYALURONATE, CARBOMER 981
• Optimizing Lymph Node Staging in Esophageal Cancer with USPIO-enhanced MRI Pending
  2023-506952-26-01 Phase II 1 country FERUMOXTRAN-10
• Optimal drug therapy for the suppression of ventricular arrhythmias in Andersen-Tawil syndrome and multifocal ectopic Purkinje-related prema… Recruiting
  2024-510682-42-01 Phase IV 1 country
• The QUEEN-IVF trial: Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open-label, randomized crossover pi… Recruiting
  2024-511190-30-00 Phase II 1 country
• Effect of antifungals on the intestinal microbiome – a randomized, controlled, proof-of-concept trial Recruiting
  2023-503710-69-00 Phase IV 1 country FLUCONAZOLE
• Soothing Pain After ChEmotherapy: Psilocybin As INtervention (SPACE-PAIN) — a randomized controlled pilot trial Recruiting
  2024-516936-93-02 Phase II 1 country DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL; OXA…
• Metformin for the prolongation of pregnancy in preterm preeclampsia: the PI-NL trial Recruiting
  2023-510382-10-00 Phase III 1 country METFORMIN HYDROCHLORIDE
• ADAPT: Treatment of Agitated behaviour in patients with Dementia non-responsive to guideline recommended interventions by Argued Personalise… Recruiting
  2024-510601-29-00 Phase IV 1 country
• FORE-PAIN trial Recruiting
  2022-500176-63-00 Phase III 1 country DICLOFENAC SODIUM; ESKETAMINE; FENTANYL CITRATE; MIDAZOLAM HYDROCHLORIDE; PARACE…
• FARE Trial Recruiting
  2023-506594-35-00 Phase IV 1 country
• Vericiguat in Vasospastic Angina (ViVA) Recruiting
  2022-502998-42-00 Phase II 1 country ACETYLCHOLINE CHLORIDE; INSULIN ASPART; SODIUM NITROPRUSSIDE DIHYDRATE; VERICIGU…
• Iberdomide combined with low-dose cyclophosphamide and dexamethasone: ICON study Recruiting
  2023-508902-66-00 Phase II 1 country CYCLOPHOSPHAMIDE MONOHYDRATE; DEXAMETHASONE; IBERDOMIDE
• REVERSE: a randomized controlled trial (RCT) to ameliorate treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Rec… Recruiting
  2024-511042-39-00 Phase II 1 country
• Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preferenc… Recruiting
  2023-509465-20-00 Phase III 1 country FLUOROURACIL; GEMCITABINE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN; PAC…
• The Hyperbaric Oxygen in HAMstring injury (HOTHAM) trial Recruiting
  2023-509610-11-00 Phase III 1 country OXYGEN
• TAP-TAU Recruiting
  2023-505430-10-00 Phase II/III 1 country FLORTAUCIPIR (18F)
• A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safet… Recruiting
  2023-509613-37-01 Phase I/II 1 country EFAVIRENZ
• PREOPANC-5 Recruiting
  2023-508707-20-00 Phase I/II 1 country FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN; PE…
• Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: the effect on comorbid eosinophilic otitis media Recruiting
  2023-508068-31-00 Phase IV 1 country DUPILUMAB
• Biomarkers for the prediction of individual CRSwNP patients' responses to mepolizumab Recruiting
  2023-508069-34-01 Phase IV 1 country MEPOLIZUMAB
• Improvement of MRI assessed cerebral Perfusion and oxygenation by luspatercept-induced Anemia Correction in non-transfusion dependent Thalas… Recruiting
  2023-504908-28-01 Phase III/IV 1 country LUSPATERCEPT
• INJECTABL-II trial: Dose finding, efficacy and immunological response of a novel immuno-adjuvant (IP-001) following microwave ablation or ir… Recruiting
  2023-504572-25-00 Phase I/II 1 country
• PEPPER-trial Recruiting
  2023-507763-18-01 Phase IV 1 country

Showing 1–24 of 47 trials